Fig. 8
The significance of TIM3/Galectin-9 pathway in DLBCL evaluated by RNA sequencing. a The correlation between TIM3/Galectin-9 enrichment and TME composition detected by CIBERSORT; b the correlation between TIM3/Galectin-9 enrichment and TIDE scores (left). The predicted response to immune checkpoint blockade therapy in high and low TIM3/Galectin-9 enrichment groups (right)